Poniard Pharmaceuticals to present its corporate overview

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Sep 16 2009

Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and chief executive officer, will provide a corporate overview at the 2009 UBS Global Life Sciences Conference on Wednesday, September 23, 2009 at 3:00 p.m. Eastern Time at the Grand Hyatt Hotel in New York City.

A live audio webcast of the corporate overview will be available for 10 business days on the "Events" page of the "News & Events" section of the Company's Web site.

Source:

http://www.poniard.com

Posted in:

Tags: , , , , , , , ,

Comments (0)

Suggested Reading

Expanding research and clinical options for children with cancer
Linking lifestyle to longevity: How diet and hypertension sway risks for heart disease and cancer
LungVax vaccine uses DNA technology to prevent lung cancer
Largest study of BRCA1 and BRCA2 carriers refines cancer risk estimates in Asian population
First-of-its-kind AI tool predicts patient response to cancer drugs at single-cell resolution
AI chatbot offers accurate answers to radiation oncology queries
How did COVID-19 impact cancer incidence trends in the US?
Research identifies how leukemia develops resistance to first line treatments

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Revolutionizing brain tumor treatment: the rise of AI in neuro-oncology